Secondary Logo

Journal Logo

Institutional members access full text with Ovid®

Indications, evolving technique, and early outcomes with robotic retroperitoneal lymph node dissection

Werntz, Ryan P.a; Pearce, Shane M.b; Eggener, Scott E.a

doi: 10.1097/MOU.0000000000000530
TESTICULAR CANCER: Edited by Aditya Bagrodia and Peter Albers
Buy

Purpose of review Examine and discuss indications, technique, and outcomes for robotic retroperitoneal lymph node dissection (RPLND) for testicular cancer.

Recent findings Open RPLND has been the longstanding standard of care for both primary and post chemotherapy RPLND. Recently, robotic RPLND has been an attractive option with the intent of reducing the morbidity associated with open surgery while providing identical oncologic efficacy. Naysayers of robotic RPLND suggest it is often inappropriately used as a staging procedure and consequently can compromise oncologic efficacy.

Summary Robotic RPLND is being evaluated as a therapeutic equivalent to open RPLND. On the basis of limited published data with modest follow-up from experienced centers, robotic RPLND appears to provide effective staging and therapeutic data mirroring that of open surgery.

aSection of Urology, Department of Surgery, The University of Chicago Medicine

bInstitute of Urology, University of Southern California, Los Angeles, California, USA

Correspondence to Ryan P. Werntz, MD, Section of Urology, Department of Surgery, The University of Chicago Medicine, 5841 S. Maryland Avenue, MC 6038, Chicago, IL 60637, USA. E-mail: ryan.werntz@uchospitals.edu

Copyright © 2018 Wolters Kluwer Health, Inc. All rights reserved.